$ACAD
ACADIA PHARMACEUTICALS INC

2015 Q3 Form 10-Q Financial Statement

#000119312515281018 Filed on August 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $39.00K $1.000K $28.00K
YoY Change 160.0% -96.43% -93.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.30M $21.10M $8.000M
YoY Change 150.62% 163.75% 220.0%
% of Gross Profit
Research & Development $18.73M $18.38M $13.80M
YoY Change 10.48% 33.19% 94.02%
% of Gross Profit
Depreciation & Amortization $120.0K $280.0K $50.00K
YoY Change 100.0% 460.0%
% of Gross Profit
Operating Expenses $39.04M $39.50M $21.75M
YoY Change 56.09% 81.59% 126.38%
Operating Profit -$39.00M -$39.50M -$21.72M
YoY Change 56.03% 81.82% 137.23%
Interest Expense $92.00K $119.0K $228.0K
YoY Change -55.77% -47.81% 200.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$38.90M -$39.40M -$21.50M
YoY Change 56.85% 83.26% 136.26%
Income Tax
% Of Pretax Income
Net Earnings -$38.91M -$39.38M -$21.50M
YoY Change 56.97% 83.2% 136.7%
Net Earnings / Revenue -99758.97% -3937800.0% -76767.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$385.9K -$392.8K -$205.2K
COMMON SHARES
Basic Shares Outstanding 100.7M shares 100.3M shares 98.98M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.7M $270.8M $354.5M
YoY Change -28.75% -23.61% 72.52%
Cash & Equivalents $70.80M $93.21M $13.70M
Short-Term Investments $169.9M $177.6M $340.8M
Other Short-Term Assets $2.000M $1.100M $3.100M
YoY Change -4.76% -64.52% 138.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $242.8M $273.4M $358.9M
YoY Change -28.8% -23.81% 73.56%
LONG-TERM ASSETS
Property, Plant & Equipment $2.068M $1.813M $500.0K
YoY Change 297.69% 262.6% 443.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $405.0K $333.0K $111.0K
YoY Change 127.53% 200.0% 98.21%
Total Long-Term Assets $2.473M $2.146M $611.0K
YoY Change 254.3% 251.23% 312.84%
TOTAL ASSETS
Total Short-Term Assets $242.8M $273.4M $358.9M
Total Long-Term Assets $2.473M $2.146M $611.0K
Total Assets $245.3M $275.5M $359.5M
YoY Change -28.22% -23.35% 73.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.204M $2.916M $1.104M
YoY Change 98.56% 164.13% -6.2%
Accrued Expenses $15.53M $16.46M $8.206M
YoY Change 53.35% 100.61% 26.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.74M $19.38M $9.339M
YoY Change 57.6% 107.5% 20.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $300.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $239.0K $340.0K $18.00K
YoY Change 1038.1% 1788.89% -99.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.74M $19.38M $9.339M
Total Long-Term Liabilities $239.0K $340.0K $18.00K
Total Liabilities $17.97M $19.72M $9.357M
YoY Change 59.43% 110.73% -63.16%
SHAREHOLDERS EQUITY
Retained Earnings -$616.8M -$577.9M -$445.0M
YoY Change 31.3% 29.87% 16.21%
Common Stock $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $227.3M $255.8M $350.1M
YoY Change
Total Liabilities & Shareholders Equity $245.3M $275.5M $359.5M
YoY Change -28.22% -23.35% 73.73%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$38.91M -$39.38M -$21.50M
YoY Change 56.97% 83.2% 136.7%
Depreciation, Depletion And Amortization $120.0K $280.0K $50.00K
YoY Change 100.0% 460.0%
Cash From Operating Activities -$31.85M -$29.87M -$16.97M
YoY Change 82.21% 76.02% 211.95%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$670.0K $0.00
YoY Change 137.5% -100.0%
Acquisitions
YoY Change
Other Investing Activities $8.490M $44.74M -$67.51M
YoY Change -78.21% -166.27% -31.5%
Cash From Investing Activities $8.310M $44.07M -$67.51M
YoY Change -78.62% -165.28% -31.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.130M 2.600M 1.720M
YoY Change -11.72% 51.16% -98.43%
NET CHANGE
Cash From Operating Activities -31.85M -29.87M -16.97M
Cash From Investing Activities 8.310M 44.07M -67.51M
Cash From Financing Activities 1.130M 2.600M 1.720M
Net Change In Cash -22.41M 16.80M -82.76M
YoY Change -198.85% -120.3% -1521.99%
FREE CASH FLOW
Cash From Operating Activities -$31.85M -$29.87M -$16.97M
Capital Expenditures -$190.0K -$670.0K $0.00
Free Cash Flow -$31.66M -$29.20M -$16.97M
YoY Change 81.95% 72.07% 215.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100714851 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13698000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100522374 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100522374 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19378000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
833696000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3528000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16462000
CY2015Q2 us-gaap Liabilities
Liabilities
19718000
CY2015Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
340000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
10000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3666000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1683000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577896000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
255821000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275539000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2916000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1813000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
273393000
CY2015Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
270542000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
86200000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93212000
CY2015Q2 us-gaap Assets
Assets
275539000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1108000
CY2015Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
177563000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
333000
CY2015Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
1508000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
177565000
CY2015Q2 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
7585000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11707000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100047331 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100047331 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15834000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
807631000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4167000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13818000
CY2014Q4 us-gaap Liabilities
Liabilities
15969000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
135000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1497000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
340000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498143000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
309489000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
325458000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2016000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
553000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
324618000
CY2014Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
322055000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61854000
CY2014Q4 us-gaap Assets
Assets
325458000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1168000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
199762000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
122023000
us-gaap Operating Expenses
OperatingExpenses
39739000
us-gaap Depreciation
Depreciation
85000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
199762000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14272000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-26000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1991000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
260647000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
287000
CY2014Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
964000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
260632000
CY2014Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
7814000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9595000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31149000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96042000 shares
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-68000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39277000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39681000
us-gaap Revenues
Revenues
58000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
570000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1261000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
358000
us-gaap Net Income Loss
NetIncomeLoss
-39323000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
46000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
288639000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7493000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
10000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
732000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1654000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-166622000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25467000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
ACAD
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11294000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-55220000
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>9. Recent Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In April 2015, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued authoritative guidance related to accounting for fees paid in a cloud computing arrangement. This accounting update provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual reporting periods beginning after December&#xA0;15, 2015 and early adoption is permitted. The Company adopted this guidance in the first quarter of fiscal 2015 with no significant impact to its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In May 2014, the FASB issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The original guidance was effective for annual reporting periods beginning after December&#xA0;15, 2016. However, in July 2015, the FASB agreed to delay the effective date by one year, with early adoption permitted, but not before the original effective date of the standard. In accordance with the agreed upon delay, the Company will adopt this guidance on January&#xA0;1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.</p> </div>
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100273000 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
46000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79733000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1662000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1115000
us-gaap Operating Income Loss
OperatingIncomeLoss
-80049000
us-gaap Revenues
Revenues
5000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
544000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-60000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
296000
us-gaap Net Income Loss
NetIncomeLoss
-79753000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
125255000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4038000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
209454000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
3000
us-gaap Operating Expenses
OperatingExpenses
80054000
us-gaap Depreciation
Depreciation
402000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4038000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45380000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31358000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22027000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
205000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
900000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2644000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
82537000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34674000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7360000 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
196800000
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9738000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99048000 shares
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21401000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21723000
CY2014Q2 us-gaap Revenues
Revenues
28000
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
228000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-21495000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
94000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
21751000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7952000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13799000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11990000 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100349000 shares
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39371000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-39497000
CY2015Q2 us-gaap Revenues
Revenues
1000
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
119000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-39378000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
39498000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21119000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7500000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18379000

Files In Submission

Name View Source Status
0001193125-15-281018-index-headers.html Edgar Link pending
0001193125-15-281018-index.html Edgar Link pending
0001193125-15-281018.txt Edgar Link pending
0001193125-15-281018-xbrl.zip Edgar Link pending
acad-20150630.xml Edgar Link completed
acad-20150630.xsd Edgar Link pending
acad-20150630_cal.xml Edgar Link unprocessable
acad-20150630_def.xml Edgar Link unprocessable
acad-20150630_lab.xml Edgar Link unprocessable
acad-20150630_pre.xml Edgar Link unprocessable
d937801d10q.htm Edgar Link pending
d937801dex31.htm Edgar Link pending
d937801dex311.htm Edgar Link pending
d937801dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending